Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 27572401)

Published in Antimicrob Agents Chemother on August 29, 2016

Authors

Jose Castillo-Mancilla1, Sharon Seifert2, Kayla Campbell2, Stacey Coleman1, Kevin McAllister2, Jia-Hua Zheng2, Edward M Gardner1, Albert Liu3, David V Glidden4, Robert Grant5, Sybil Hosek6, Craig M Wilson7, Lane R Bushman2, Samantha MaWhinney8, Peter L Anderson9

Author Affiliations

1: Division of Infectious Diseases, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
2: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
3: Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA.
4: Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
5: Gladstone Institute, University of California, San Francisco, California, USA.
6: Department of Psychiatry, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA.
7: Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
8: Department of Biostatistics and Bioinformatics, Colorado School of Public Health, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
9: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA peter.anderson@ucdenver.edu.

Associated clinical trials:

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status | NCT01040091

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots (DOT-DBS) | NCT02022657

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis | NCT01772823

Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy (2104) | NCT02012621

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant | NCT04530630

Testing of the Smartphone App to Enhance HIV Prevention Cascade Among Malaysian MSM | NCT05044013

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2013) 13.72

Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med (2016) 2.86

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41

The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 2.19

Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10

Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 2.04

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89

Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis (2014) 1.16

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses (2015) 1.08

Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal (2016) 0.90

Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. J Infect Dis (2015) 0.89

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrob Agents Chemother (2015) 0.85